<DOC>
	<DOCNO>NCT00648557</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's levothyroxine sodium 200 μg tablet Abbott 's Synthroid® 200 μg tablet follow single 600 μg ( 3 x 200 μg ) dose administration healthy volunteer fast condition . Twenty-nine healthy , non-smoking , subject age 18 47 complete open-label , randomize , two-period , two-treatment , single-dose crossover study conduct Dr. James D. Carlson PRACS Institute , Ltd. , Fargo , ND . Statistical analysis data reveal 90 % confidence interval within acceptable bioequivalent range 80 % 125 % natural log transform parameter LNAUC0-48hr LNCPEAK baseline correct total L-thyroxine . This study demonstrate Mylan 's 200 μg levothyroxine sodium tablet bioequivalent Abbott 's Synthroid® 200 μg tablet follow single , oral 600 μg ( 3 x 200 μg ) dose fast condition</brief_summary>
	<brief_title>Fasting Study Levothyroxine Sodium Tablets 200 mg Synthroid Tablets 200 mg</brief_title>
	<detailed_description />
	<criteria>1 . Age : 1850 year . 2 . Sex : Men and/or nonpregnant , nonlactating woman . 1 . Women childbearing potential must negative serum β human chorionic gonadotropin ( HCG ) pregnancy test perform within 14 day prior study even prior dose administration . An additional serum ( β HCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . Oral contraceptive use within 3 month prior dose throughout course study due fact increase serum TBG concentration , therefore , elevate T4 . Acceptable form contraception include follow : 1. intrauterine device place least 3 month prior start study remain place study period , 2. barrier method contain use conjunction spermicidal agent , 3. postmenopausal accompany document postmenopausal course least one year surgical sterility ( tubal ligation , oophorectomy hysterectomy ) . 3 . Weight : At least 60 kg ( 132 lb ) men 48 kg ( 106 lb ) woman , within 15 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1983 ( See Part II Administrative Aspects Bioequivalence Protocols ) . 4 . All subject judge normal ( euthyroid ) healthy prestudy medical evaluation ( physical examination , laboratory evaluation , blood chemistry , serum T4 ( free total ) , serum T3 ( total ) , serum thyroidstimulating hormone ( TSH ) , serum thyroxinebinding globulin ( TBG ) , hepatitis B hepatitis C test , HIV test , 12lead ECG , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine , methadone ) perform within 14 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within 1 year initial study drug administration . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamin within 48 hour prior initial dose study medication . 4 . Any change dietary exercise habit throughout duration study . 3 . Medications : 1 . Use medication within last 30 day prior initial dose study medication , study washout period . These may include limited : infant soybean formula , steroid , salicylate , androgenic estrogenic hormone include oral contraceptive ; preparation contain iodine , vitamin ; oral antidiabetic agent ; resins lower cholesterol , cholestyramine ; sucralfate , propranolol , amiodarone , phenytoin , carbamazepine , furosemide ; aluminumcontaining antacid , include aluminum hydroxide ; rifampin , calcium channel blocker ferrous sulfate . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant chronic disease and/or hepatitis . 2 . History drug and/or alcohol abuse . 3 . Acute illness time either prestudy medical evaluation dosing . 4 . History thyroid disease . 5 . Subjects underlie medical condition know interfere absorption metabolism thyroid hormone . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II Administrative Aspects Bioavailability Protocols ) . 2 . Abnormal clinically relevant ECG tracing . 3 . Abnormal thyroid function test . 6 . Donation loss significant volume blood plasma ( &gt; 450 ml ) within 28 day prior initial dose study medication . 7 . Subjects receive surgical treatment within 6 month prior initial dose study medication . 8 . Subjects know allergy hypersensitivity thyroid preparation . 9 . Subjects receive investigational drug within 30 day prior initial dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>